Promising Results from Combination Therapy for Pancreatic Cancer
STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate
Image: Stat
A new clinical trial shows that a combination of Tango Therapeutics' vopimetostat and Revolution Medicines' daraxonrasib has led to durable responses in most pancreatic cancer patients, marking a significant advancement in treatment options.
- 01Revolution Medicines' drug has gained attention for its effectiveness in treating pancreatic cancer.
- 02Tango Therapeutics reported the results of an early-stage clinical trial involving vopimetostat.
- 03The combination therapy showed durable responses in a large majority of patients.
- 04This marks a significant milestone in the oncology field for pancreatic cancer treatments.
- 05The collaboration highlights the potential of combining therapies to enhance patient outcomes.
Advertisement
In-Article Ad
Recent data from an early-stage clinical trial indicates that a combination of Tango Therapeutics' vopimetostat and Revolution Medicines' daraxonrasib has resulted in durable responses among a significant number of pancreatic cancer patients. This combination therapy has generated excitement in the oncology community, as it showcases unprecedented outcomes for patients suffering from this aggressive cancer. The trial results were announced on Monday, emphasizing the potential of this collaborative approach in improving treatment options for pancreatic cancer, which has historically been challenging to treat effectively. The findings suggest a promising avenue for further research and development in cancer therapies.
Advertisement
In-Article Ad
This combination therapy could significantly improve treatment outcomes for pancreatic cancer patients, which is a critical area of need in oncology.
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of combination therapies in cancer treatment?
Connecting to poll...
More about Revolution Medicines
New Pancreatic Cancer Drug Daraxonrasib Receives Enthusiastic Reception at ASCO 2026
Newsweek • Jun 2, 2026
Advancements in Cancer Treatment and China's Biotech Growth Highlighted at ASCO
Stat • Jun 1, 2026
Les actions de Nvidia et Revolution Medicines en hausse, Redwire Corp. en baisse
Investing French • Jun 1, 2026
Read the original article
Visit the source for the complete story.